The human microbiome is rapidly moving from scientific promise to clinical reality. From immunity and oncology to cardiometabolic and women's health, new microbiome-based therapies are reshaping the boundaries of modern medicine.
This new IQVIA white paper explores the strongest clinical signals, investor sentiment, and the eight success factors shaping the future of microbiome therapeutics — from regulatory clarity and robust evidence to manufacturing, patient-centred design and ecosystem collaboration. Get your copy now to see how science, policy and investment are converging to unlock the field's full potential.
Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.
Evidence-based solutions that challenge the status quo.
.svg){kind=icon}
